NDAORALTABLET
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PATHILON (tridihexethyl chloride) is an oral anticholinergic agent approved in 1954 for treatment of gastrointestinal and urinary tract disorders. It works by blocking acetylcholine receptors to reduce smooth muscle spasms and secretions. The drug is a legacy small molecule with limited modern clinical use.
LOE Approaching
This legacy product operates in a mature, declining market with minimal commercial investment; minimal team expansion expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PATHILON offers minimal career upside; the product is in end-of-life phase with zero linked job openings and declining market relevance. Roles focus on maintenance and managed decline rather than growth or innovation.
Brand ManagerProduct Manager
Worked on PATHILON at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.